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A B S T R A C T
Purpose: A proportion of patients with childhood and juvenile absence epilepsies (CAE, JAE) are likely to
be classiﬁed as medically refractory. In view of evidence gap for the treatment of such patients, this series
is reported to generate estimate for efﬁcacy of vagus nerve stimulation (VNS) in this patient population.
Methods: Patients were identiﬁed by a chart review of all VNS recipients between January 1, 2006 and
December 31, 2011. The diagnosis of CAE and JAE was based on conventional criteria. Details of
demography, epilepsy phenomenology, management and outcomes were extracted. The outcome
measures included reduction in daily seizure frequency measured as a percentage of pre-VNS seizure
frequency and classiﬁed on International League Against Epilepsy (ILAE) outcome scale.
Results: Nine patients (7 CAE, 2 JAE) with a mean age of seizure onset of 5.4 years (3.9) were identiﬁed.
Mean duration of epilepsy prior to VNS implant was found to be 3.9 years (1.4). These patients had failed a
median of 5 anti-epileptic drugs before being referred for consideration of surgical treatment. After a mean
follow-up of 33.9 months (25.5, minimum 4 months), 1 patient attained complete seizure freedom (ILAE
class 1), 6 had ILAE class 4 and 2 had ILAE class 5 outcomes, respectively. Mean reduction in daily seizure
frequency was found to be 53.5  60.3% (1-sided p-value for paired t-test = 0.04), with a 50% responder rate
of 55.6%.
Conclusion: VNS may be considered as a therapeutic option in patients with medically refractory
absence epilepsy.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Absence seizures, characterized by frequent brief staring
episodes, are commonly encountered in a number of pediatric
idiopathic generalized epilepsy syndromes including childhood
and juvenile absence epilepsies (CAE, JAE), and juvenile myoclonic
epilepsy. Usually, CAE and JAE are considered benign, drug
responsive, age-limited entities. However, up to 20% of patients
may not achieve seizure remission with adequate drug therapy.1 In
the landmark CAE study, the freedom-from-failure rates were 53%
and 58%, respectively for ethosuximide and valproic acid, after 16
weeks of therapy.2 Thus, a proportion of patients with these
syndromes may qualify as having drug resistant epilepsy by
International League Against Epilepsy (ILAE) deﬁnition.3 Further,
approximately 10% of patients with CAE and 24% with JAE do not* Corresponding author at: Comprehensive Epilepsy Center, Division of
Neurology, Cincinnati Children’s Hospital Medical Center, ML 2015, 3333 Burnet
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http://dx.doi.org/10.1016/j.seizure.2013.01.008experience age related remission.4 There is markedly limited
information about management of such patients with medically
refractory absence epilepsies. In a recent series of 12 patients, 6
(50%) had >90% seizure reduction at 12 months of treatment with
amantadine.5 However, in this study, 3 patients discontinued
amantadine within 6 months due to lack of efﬁcacy. Three
additional patients reported signiﬁcant adverse effects including
behavioral changes, headache, dizziness and weight loss.5 There
have been 2 earlier isolated uncontrolled reports of use of
amantadine for absence seizures unresponsive to usual AED.6,7
Besides these studies, there is paucity of evidence for efﬁcacy of
other treatment options for children with medically refractory
absence epilepsies.
These epilepsies have primarily generalized ictal onset and
these patients are not usually thought to be candidates for
resective epilepsy surgery. However, vagus nerve stimulation
(VNS) has been tried in adults with medically refractory
generalized epilepsies including patients with absence seizures.
In a series of 12 patients, 58% decrease in frequency of absence
seizures was noted after a mean follow-up of 23 months.8 In some
other reports of use of VNS for treatment of adults with medically
refractory generalized epilepsy, the outcome for absence seizuresvier Ltd. All rights reserved.
Table 1
Clinical proﬁles and outcomes of patients with refractory absence epilepsy treated with vagus nerve stimulation.
Patient
#
Age
(years)
Sex Age at SZ
onset (years)
Age at
VNS
(years)
Duration
(years)
Frequency
(per day)
AED# AED at
referral (past)
Follow-up
(months)
ILAE
outcome
%
Reduction
EEG
outcome
1 28 M – 23.39 – 25 3 LTG, VPA LOST 5 40 No change
2 14 M 6 9.47 3.47 200 3 FLB, ZNS 62 4 90 Improved
3 13 M 4.5 8.42 3.92 24 4 LTG 61 4 55 No change
4 13 M 4.5 8.42 3.92 10 4 LTG 56 4 55 No change
5 9 M 1.8 4.28 2.48 15 5 CLN, LTG, VPA 47 1 100 Improved
6 13 F 8 11.25 3.25 23 6 PHT (GBP, FLB, LEV,
TPM, VPA)
26 5 74 Worse
7 9 M 0.5 7.26 6.76 50 21 LOR, RUF, VPA
(18 OTHER AED)
4 4 80 Improved
8 12 M 5 9.53 4.53 100 8 AMANTADINE (CLN,
ETX, LEV, LTG,
OXC, TPM, ZNS)
7 4 50 No change
9 17 F 13 15.61 2.61 60 5 ETX, FLB, LEV, LOR 8 4 88 Improved
AED: anti-epileptic drug; ILAE: International League Against Epilepsy; SZ: seizure; VNS: vagus nerve stimulation; CLN: clonazepam; GBP: gabapentin; ETX: ethosuximide;
FLB: felbamate; LEV: levetiracetam; LOR: lorazepam; LTG: lamotrigine; OXC: oxcarbazepine; PHT: phenytoin; RUF: ruﬁnamide; TPM: topiramate; VPA: valproate; ZNS:
zonisamide.
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children, this case series is reported to estimate the efﬁcacy of VNS
in patients with medically refractory absence epilepsy.
2. Methods
Patients were identiﬁed by a retrospective chart review of all
VNS device recipients between January 1, 2006 and December 31,
2011. The lower cut-off date was chosen because electronic
medical records (EMR) system was installed at that time ensuring
uniformity of information and ease of access. Additionally, since
then all the VNS device insertions were performed by a single
neurosurgeon (FTM). All patients diagnosed with absence epilepsy
based on clinical features, EEG ﬁndings and a normal MRI of the
brain, were eligible for inclusion if they received a VNS during the
study period. Speciﬁcally, the diagnosis of CAE/JAE was based on
ILAE revised classiﬁcation of epilepsy syndromes, including
frequent clinical absence seizures and characteristic EEG pattern.11
The extracted data comprised of demographic variables
including age, sex, age at onset of seizures, duration of epilepsy
prior to VNS implant, age at VNS implant; and, clinical details
including daily seizure frequency, seizure types in addition to
absence seizures, developmental delay or intellectual disability,
epilepsy syndrome, and failed AED including those at referral. Both
initial and follow-up seizure frequencies obtained from EMR charts
were based on parental reporting. The outcome measures included
reduction in daily seizure frequency measured as a percentage of
pre-VNS seizure frequency and classiﬁed on ILAE outcome scale.12
Lengths of follow-up and technical complications related to VNS
device were also noted. EEG outcome was obtained from reports
available in EMR for routine EEG. It was classiﬁed as improved,
unchanged or worse based on frequency and duration of spike-
wave bursts, and, presence, number and duration of electrographic
or electro-clinical seizures. The data was recorded in an Excel
(Microsoft Corp., Redmond, WA) spreadsheet. Appropriate sum-
mary statistics were calculated for all variables.
Neurocybernetic prosthesis (NCP) system (Cyberonics Inc.,
Houston, TX), implanted with standard surgical technique was
used for left vagus nerve stimulation.13,14 The device was switched
on in immediate post-operative period with the following settings:
current 0.25 mA, frequency 20–30 Hz, pulse width 250–500 ms, on
time 30 s, off time 5 min. At follow-up visits every 1–3 months, the
current was gradually increased by 0.25 mA until patient toler-
ance, seizure freedom or a maximum of 2.5 mA was achieved. The
magnet output current was always programmed to be 0.25–0.5 mA
higher than automatic stimulation, with a pulse width of 500 msfor a period of 60 s. Changes in concurrent anti-seizure medica-
tions or the decision to go for ‘‘rapid cycling’’, were at the discretion
of treating neurologist.
3. Results
A total of 9 patients (7 males) with a mean age of 14.2 years
(5.7) were found, with mean age of seizure onset of 5.4 years (3.9).
The mean duration of epilepsy prior to VNS implant in these patients
was 3.9 years (1.4), with the mean age at VNS implantation being
10.8 years (5.6). Clinically, 7 of the patients were classiﬁed as having
CAE and 2 as JAE. The median seizure frequency based on parental
reporting was found to be 25/day (inter-quartile range 61). Although
3 of the patients had generalized tonic–clonic seizures (GTCS) in
addition to absence seizures, only 1 had a past history of status
epilepticus. Two of the patients had borderline to mild developmental
delay or intellectual disability. Prior to surgical referral, these patients
had failed 3–21 AED (median = 5, Table 1). Three patients had
functional neuroimaging as a part of their pre-surgical evaluation,
which showed discordant data among different modalities.
These patients had follow-up for a mean duration of 33.9
months (25.5, minimum 4 months). One patient attained complete
seizure freedom (ILAE class 1), 6 had ILAE class 4 and 2 had class 5
outcomes, respectively. Mean reduction in daily seizure frequency
was observed to be 53.5  60.3% (1-sided p-value for paired t-
test = 0.04), with 5 patients (55.6%) having a reduction of 50%. Only
1 patient had increased seizure frequency after a follow-up of 26
months (Table 1). EEG improved in 4 (44.4%) patients, with complete
normalization in 1 (patient with complete seizure remission). It was
classiﬁed as unchanged in 4 (44.4%) other patients, though on
subjective review there was reduction in frequency of spike-wave
bursts. One patient showed worsening of EEG with deterioration of
background rhythm (patient with increased seizure frequency,
Table 1). Two patients (22.2%) had lead fractures as a device related
adverse event and the hardware needed to be replaced.
4. Discussion
This case series provides preliminary evidence for efﬁcacy of VNS
in children with medically refractory absence epilepsy, with 54%
mean reduction in daily seizure frequency and a 50% responder rate
of 56%, after a mean follow-up of about 3 years. The EEG outcome
showed agreement with clinical response (Table 1). Our observa-
tions broadly agree with previously published experience with VNS
in refractory idiopathic generalized epilepsy (IGE). In the E04 cohort,
there was 60% reduction in mixed seizure burden in 7 patients with
Table 2
Efﬁcacy of VNS in medically refractory generalized epilepsy.
Author,
year
N
(females)
Age (years,
mean  SD)
Age at seizure
onset (years,
mean  SD)
Duration
(years, mean,
range)
AED#
(mean,
range)
Follow-up
(months,
mean, range)
Overall
reduction
50%
Responder
rate
Comments
Labar, 1999 24 (11) 18 (4–40)a 2 (0–14)a 15 (4–35)a 2 (1–5)a 3 46% 46% Data from E04 study;
7 patients had IGE;
reduction: IGE 60%,
absence seizures 81%
Holmes, 2004 16 (7) 36  11.3 7.5  4.8 6–49 7.5 (2–15) 12–21 43.3% 43.80% 8 patients had IGE;
reduction in IGE 42.9%
Kostov, 2007 12 (10) 30.7  14.4 10.8 (3–20)b 20.6 (4–43) 8.8 (6–14) 23.2 (9–54) 61% 67% All patients had IGE
(7 JME, 3 JAE); reduction
in absence seizures 58%
Present Study 9 (2) 14.2  5.7 5.4  3.8 3.9 (2.5–6.8) 5 (3–21)a 33.9 (4–62) 53.5% 55.60% 6 patients had CAE; 3 JAE
AED: anti-epileptic drug(s); CAE: childhood absence epilepsy; IGE: idiopathic generalized epilepsy; JAE: juvenile absence epilepsy; JME: juvenile myoclonic epilepsy; SD:
standard deviation.
a Represents median, instead of mean.
b Did not provide SD, hence range is given.
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was reported in another series of 12 patients with longer (mean 23.2
months) follow-up.8 However, Holmes et al. reported only 42.9%
decrease in seizure frequency in their 8 patients after a follow-up of
12–21 months.9 This difference in efﬁcacy probably results from
heterogeneity of patient populations, especially in ages of onset of
seizures (Table 2). The proportion of patients experiencing 50%
reduction in seizure frequency was found to be 56%. This ﬁgure is
also comparable to other studies, as for mixed seizure types, 50%
responder rate has varied from 44% to 67% (Table 2). Although
stimulation related adverse effects have been commonly documen-
ted, there is limited reporting of device related complications. In our
series, 2 patients had lead fractures suspected initially due to
abnormally high impedance. In a larger (n = 105) study looking at
operative and technical complications with VNS, lead fracture was
noted to be the most frequent technical complication (7.6%).16More
interestingly, the hardware failure was observed exclusively in
children.16
The present study has some inadvertent limitations. As in any
retrospective review, the observed decrease in seizure burden
cannot be attributed to VNS causally, as changes in drug therapy
and variation in device settings are important confounding factors.
Secondly, regarding ascertainment of seizure burden, we relied on
parental reporting as documented in EMR. While recognized to be
imperfect,17 this was the best available measure to us. Some of the
other investigators have used better methods to quantify seizure
frequency e.g. in the E04 cohort, a baseline period of video-EEG
monitoring was used.15 This was not feasible for us. Finally, we
have reported the decrease in mixed seizure burden and not
separately for absence seizures. However, we believe that it is
unlikely to distort clinical interpretation, since only 3 patients had
GTCS and the frequency was much less than absence seizures.
Two patients in our study had onset before 2 years of age and
mild developmental delay. The diagnosis of CAE can be challenged
in these patients, though they had typical absence seizures and
characteristic EEG pattern. Regarding cognitive problems in these
2 patients, multiple AED and high seizure burden could have been
potentially contributory factors. However, the combination of
atypical features like early onset and intellectual disability should
prompt further evaluation for etiology, since absence seizures have
been recognized as a clinical feature in some speciﬁc disorders
including recently in GLUT1 deﬁciency.18
Conventionally, CAE and JAE are regarded as pharmacotherapy
responsive, age-limited syndromes. However, approximately 10%
of patients with CAE do not have spontaneous remission.4 In a
Swedish population-based study, a 91% remission rate was
observed in CAE patients with only absence seizures.19 Otherstudies have suggested that up to 6% of patients with CAE, can have
persistent absence seizures even in middle and late adulthood.4
Further, up to 60% of patients with onset of typical absence seizures
in childhood have later onset GTCS in addition.4,20,21 Hence,
remission of only absence seizures may not mean complete seizure
freedom. In JAE especially with 10 or more GTCS, up to 24% may not
achieve remission, though the prognosis is better in those with
only absence seizures or rare GTCS.4,22 These ﬁgures represent
conservative estimates based on strict case deﬁnitions.4 In
practice, children with IGE syndromes present with considerable
variation and overlapping features. This group is particularly likely
to have a proportion of patients at risk for medical intractability.
Unfortunately, there is remarkable paucity of systematic evidence
for therapeutic options in such patients. Hence, we believe that the
ﬁndings generated in this report are clinically important because it
included relatively homogenous patient population with absence
epilepsies and had a longer average follow-up as compared to
previous data (Table 2). Based on limited evidence, VNS may be
considered as a treatment option in patients with medically
refractory absence epilepsy, where spontaneous remission appears
unlikely based on clinical course.
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